NCT02390882

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH

A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 494 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia

Detailed description

A multicenter, randomized, double-blind, phase 3 clinical trial to evaluate the efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with benign prostatic hyperplasia

Conditions

• Benign Prostate Hyperplasia

Interventions

Type	Name	Description
DRUG	Placebo	Placebo
DRUG	HGP0412 capsule	Tamsulon high dose
DRUG	HIP1402 capsule	Tamsulon high dose

Timeline

• Start date: 2014-10-01
• Primary completion: 2015-05-01
• Completion: 2015-07-01
• First posted: 2015-03-18
• Last updated: 2016-10-13

Locations

1 site across 1 country: South Korea